Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | NRP1 | O14786 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748477 | 0.90 | KCNH2 (0.53) | KCNH2PIK3C3NRP1SCN9APARP14 | |
| SCHEMBL2748212 | 0.90 | KCNH2 (0.70) | KCNH2PARP14SLC10A6LMNAALDH1A1 | |
| SCHEMBL4547553 | 0.82 | KCNH2 (0.43) | KCNH2PIK3C3NRP1SCN9AWDR5 | |
| SCHEMBL2747486 | 0.73 | KCNH2 (0.53) | KCNH2NRP1PARP14WDR5KDM4E | |
| SCHEMBL2747534 | 0.73 | KCNH2 (0.70) | KCNH2PARP14SLC10A6LMNAKDM4E | |
| SCHEMBL1199270 | 0.71 | KCNH2 (1.00) | KCNH2NRP1PARP14SLC10A6LMNA | |
| SCHEMBL2747281 | 0.71 | KDM1A (0.55) | LMNAKDM4EALDH1A1KDM1AACLY | |
| SCHEMBL2748805 | 0.70 | LMNA (0.67) | KCNH2SLC10A6LMNAKDM4EALDH1A1 | |
| SCHEMBL1199591 | 0.70 | KCNH2 (0.80) | KCNH2PARP14SLC10A6LMNAALDH1A1 | |
| SCHEMBL2748631 | 0.70 | KCNH2 (0.60) | KCNH2NRP1PARP14SLC10A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | KCNH2 4765/4885PIK3C3 3160/4885NRP1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.